Palvella Therapeutics, Inc. (FRA:PI6)

Germany flag Germany · Delayed Price · Currency is EUR
85.50
0.00 (0.00%)
At close: Nov 28, 2025
567.97%
Market Cap1.05B
Revenue (ttm)n/a
Net Income (ttm)-27.59M
Shares Outn/a
EPS (ttm)-3.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume6
Open85.50
Previous Close85.50
Day's Range85.50 - 85.50
52-Week Range11.80 - 86.00
Betan/a
RSI68.56
Earnings DateMar 31, 2026

About Palvella Therapeutics

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Way... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Wesley Kaupinen
Employees 14
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PI6
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.